Prevention of hepatocarcinogenesis after combinatoin therapy with daclatasvir and asunaprevir : A pilot study in usefulness of a small amount of Peg-interfero
Not Applicable
- Conditions
- Among genotye 1b HCV infected patients who achieved SVR in combination therapy with daclatasvir and asunaprevir, patients that serum AFP value is greater than or equal to 6.0 ng / mL at post-treatment 24 weeks
- Registration Number
- JPRN-UMIN000018855
- Lead Sponsor
- Department of Gastroenterology & Hepatology, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
patients with HCC
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method level of serum AFP
- Secondary Outcome Measures
Name Time Method